Literature DB >> 26122200

[Neuroleptic malignant syndrome : Rare cause of fever of unknown origin].

R Chackupurakal1, U Wild, M Kamm, F Wappler, D Reske, S G Sakka.   

Abstract

Neuroleptic malignant syndrome (NMS) is a possible cause of fever of unknown origin (FUO) and is a potentially fatal adverse effect of various drugs, especially of neuroleptics. First generation antipsychotics, such as received by the patient described in this article, are more likely to cause NMS than second generation antipsychotics. The key symptoms are the development of severe muscle rigidity and elevated temperature associated with the use of neuroleptic medication. Malignant catatonia (MC) is an important differential diagnosis of NMS. While neuroleptics can trigger NMS and must be immediately discontinued if NMS occurs, neuroleptic therapy represents the first line treatment for MC. This article describes the case of a patient with schizoaffective disorder where initially the diagnosis of NMS was not clear. Eventually, fever and a markedly elevated serum creatine kinase (CK) led to the correct diagnosis and the appropriate therapy with dantrolene, bromocriptine and amantadine. Furthermore, a thorough review of the currently available literature on NMS is provided.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26122200     DOI: 10.1007/s00101-015-0046-2

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  20 in total

1.  Fever of unexplained origin: report on 100 cases.

Authors:  R G PETERSDORF; P B BEESON
Journal:  Medicine (Baltimore)       Date:  1961-02       Impact factor: 1.889

2.  NMS and genetic drug oxidation.

Authors:  K Otani; S Kaneko; Y Fukushima; K Chiba; T Ishizaki
Journal:  Br J Psychiatry       Date:  1991-10       Impact factor: 9.319

3.  Yield of bone marrow examination in diagnosing the source of fever of unknown origin.

Authors:  Arnaud Hot; Isabelle Jaisson; Charlotte Girard; Martine French; Denis Vital Durand; Hugues Rousset; Jacques Ninet
Journal:  Arch Intern Med       Date:  2009-11-23

4.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

5.  Treatment of neuroleptic malignant syndrome with electroconvulsive therapy.

Authors:  A Lazarus
Journal:  J Nerv Ment Dis       Date:  1986-01       Impact factor: 2.254

6.  Neuroleptic malignant syndrome.

Authors:  S N Caroff; S C Mann; A Lazarus
Journal:  Arch Gen Psychiatry       Date:  1987-09

7.  Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia.

Authors:  Mehdi Mirsaeidi; Paula Peyrani; Stefano Aliberti; Giovanni Filardo; Jose Bordon; Francesco Blasi; Julio A Ramirez
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

8.  Neuroleptic malignant syndrome: a preventive program.

Authors:  M L Fernando; R Manchanda; C Kirk
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

9.  ECT in the neuroleptic malignant syndrome: case report.

Authors:  S S Jessee; G F Anderson
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

Review 10.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03
View more
  2 in total

1.  [33-year-old female with postanesthesia unconsciousness, tachycardia and excessively warm skin : Preparation for the medical specialist examination: part 47].

Authors:  R Chackupurakal; F Wappler; S G Sakka
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

Review 2.  Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia.

Authors:  Giuseppe Caruso; Margherita Grasso; Annamaria Fidilio; Fabio Tascedda; Filippo Drago; Filippo Caraci
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.